Graves’ disease: introducing new genetic and epigenetic contributors

in Journal of Molecular Endocrinology
View More View Less
  • 1 E Razmara, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)
  • 2 M Salehi, Faculty of medicine, Shahrekord University of Medical Science, Shahrekord, Iran (the Islamic Republic of)
  • 3 S Aslani, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)
  • 4 A Bitaraf, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)
  • 5 H Yousefi, Department of Biochemistry and Molecular Biology, LSU, Baton Rouge, United States
  • 6 J Colón, Department of Biochemistry and Molecular Biology, LSU, Baton Rouge, United States
  • 7 M Mahmoudi, Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of)

Correspondence: Mahdi Mahmoudi, Email: mahmoudim@tums.ac.ir

Autoimmune thyroid disease (AITD) accounts for 90% of all thyroid diseases and affects 2-5% of the population with remarkable familial clustering. Among AITDs, Graves’ disease (GD) is a complex disease affecting thyroid function. Over the last two decades, case-control studies using cutting-edge gene sequencing techniques have detected various susceptible loci that may predispose individuals to GD. It has been presumed that all likely associated genes, variants, and polymorphisms might be responsible for 75-80% of the heritability of GD. As a result, there are implications concerning the potential contribution of environmental and epigenetic factors in the pathogenesis of GD, including its initiation, progression, and development. Numerous review studies have summarized the contribution of genetic factors in GD until now, but there are still some key questions and notions that have not been discussed concerning the interplay of genetic, epigenetic, and immunological factors. With this in mind, this review discusses some newly-identified loci and their potential roles in the pathogenicity of GD. This may lead to the identification of new, promising therapeutic targets. Here, we emphasized principles, listed all the reported disease-associated genes and polymorphisms, and also summarized the current understanding of the epigenetic basis of GD.

 

Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 471 471 293
Full Text Views 0 0 0
PDF Downloads 0 0 0